以壳聚糖为佐剂的幽门螺杆菌疫苗的免疫治疗作用
http://www.100md.com
谢 勇, 龚燕锋, 周南进, 陈 江, 吕农华, 梅承誉, 侯晓华
幽门螺杆菌;壳聚糖;治疗性疫苗;佐剂,谢勇,侯晓华,谢勇,龚燕锋,陈江,吕农华,梅承誉,周南进,谢勇,通讯作者:,电话:,收稿日期:,接受日期:,ImmunetherapeuticeffectofHelicobacterpylori
参见附件(1kb)。
谢勇, 侯晓华, 华中科技大学同济医学院附属协和医院消化科 湖北省武汉市 430022
谢勇, 龚燕锋, 陈江, 吕农华, 梅承誉, 南昌大学第一附属医院消化系病研究所 江西省南昌市 330006
周南进, 江西省医学科学研究所生物化学研究室 江西省南昌市 330006
谢勇, 华中科技大学同济医学院附属协和医院在职博士生, 主要从事消化系疾病的基础与临床研究.国家自然科学基金资助项目, No. 30460052
江西省学科带头人培养项目, No. K010501
通讯作者: 候晓华, 430022, 湖北省武汉市, 湖北省武汉市华中科技大学同济医学院附属协和医院消化科.
houxh@public.wh.hb.cn
电话: 0791-8692507
收稿日期: 2006-11-25 接受日期: 2006-12-22
Immune therapeutic effect of Helicobacter pylori vaccine with chitosan adjuvant
Yong Xie, Yan-Feng Gong, Nan-Jin Zhou, Jiang Chen, Nong-Hua Lv, Cheng-Yu Mei, Xiao-Hua Hou
Yong Xie, Xiao-Hua Hou, Department of Gastroenterology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China
Yong Xie, Yan-Feng Gong, Jiang Chen, Nong-Hua Lv, Cheng-Yu Mei, Institute of Digestive Diseases, the First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China
Nan-Jin Zhou, Department of Biochemistry, Jiangxi Institute of Medical Sciences, Nanchang 330006, Jiangxi Province, China
Supported by National Natural Science Foundation of China, No. 30460052, and the Foundation for Subject Leader Program of Jiangxi Province, No. K010501
Correspondence to: Xiao-Hua Hou, Department of Gastroenterology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China. houxh@public.wh.hb.cn
Received: 2006-11-25 Accepted: 2006-12-22
AbstractAIM:To investigate the roles of H pylori vaccine with chitosan as adjuvant in the immunological therapy of H pylori infection.
METHODS: Female BALB/c mice infected H pylori were randomly divided into group A, B, C, D and E, which were treated with phosphate buffered saline (PBS),H pylori antigen, H pyloriantigen plus chitosan solution,H pylori antigen plus chitosan particles, and H pylori antigen plus cholera toxin (CT), respectively. The vaccine was orally given once a week for 4 weeks. At the 4th week after the last immunization, these mice were killed and gastric mucosa were embedded in paraffin, then assayed with Giemsa and HE staining. At the same time, quantitative H pylori culture was performed, and enzyme-linked immunosorbnent assay (ELISA) was used to detect anti-H pylori IgA in saliva and gastric mucosa and anti-H pylori IgG in serum.
RESULTS: In the groups with chitosan as adjuvant, the eradication of H pylori was achieved in 58.33% mice, which was in accordance with that in the group with CT as adjuvant (45.45%), and the colonization density of H pylori in the groups with chitosan as adjuvant was significantly lower than that in the other groups (F = 24.166, P < 0.05-0.001). The degrees of acute inflammation in gastric mucosal were significantly lower in mice with adjuvant than those in group A and B (H = 21 ......
谢勇, 侯晓华, 华中科技大学同济医学院附属协和医院消化科 湖北省武汉市 430022
谢勇, 龚燕锋, 陈江, 吕农华, 梅承誉, 南昌大学第一附属医院消化系病研究所 江西省南昌市 330006
周南进, 江西省医学科学研究所生物化学研究室 江西省南昌市 330006
谢勇, 华中科技大学同济医学院附属协和医院在职博士生, 主要从事消化系疾病的基础与临床研究.国家自然科学基金资助项目, No. 30460052
江西省学科带头人培养项目, No. K010501
通讯作者: 候晓华, 430022, 湖北省武汉市, 湖北省武汉市华中科技大学同济医学院附属协和医院消化科.
houxh@public.wh.hb.cn
电话: 0791-8692507
收稿日期: 2006-11-25 接受日期: 2006-12-22
Immune therapeutic effect of Helicobacter pylori vaccine with chitosan adjuvant
Yong Xie, Yan-Feng Gong, Nan-Jin Zhou, Jiang Chen, Nong-Hua Lv, Cheng-Yu Mei, Xiao-Hua Hou
Yong Xie, Xiao-Hua Hou, Department of Gastroenterology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China
Yong Xie, Yan-Feng Gong, Jiang Chen, Nong-Hua Lv, Cheng-Yu Mei, Institute of Digestive Diseases, the First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China
Nan-Jin Zhou, Department of Biochemistry, Jiangxi Institute of Medical Sciences, Nanchang 330006, Jiangxi Province, China
Supported by National Natural Science Foundation of China, No. 30460052, and the Foundation for Subject Leader Program of Jiangxi Province, No. K010501
Correspondence to: Xiao-Hua Hou, Department of Gastroenterology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China. houxh@public.wh.hb.cn
Received: 2006-11-25 Accepted: 2006-12-22
AbstractAIM:To investigate the roles of H pylori vaccine with chitosan as adjuvant in the immunological therapy of H pylori infection.
METHODS: Female BALB/c mice infected H pylori were randomly divided into group A, B, C, D and E, which were treated with phosphate buffered saline (PBS),H pylori antigen, H pyloriantigen plus chitosan solution,H pylori antigen plus chitosan particles, and H pylori antigen plus cholera toxin (CT), respectively. The vaccine was orally given once a week for 4 weeks. At the 4th week after the last immunization, these mice were killed and gastric mucosa were embedded in paraffin, then assayed with Giemsa and HE staining. At the same time, quantitative H pylori culture was performed, and enzyme-linked immunosorbnent assay (ELISA) was used to detect anti-H pylori IgA in saliva and gastric mucosa and anti-H pylori IgG in serum.
RESULTS: In the groups with chitosan as adjuvant, the eradication of H pylori was achieved in 58.33% mice, which was in accordance with that in the group with CT as adjuvant (45.45%), and the colonization density of H pylori in the groups with chitosan as adjuvant was significantly lower than that in the other groups (F = 24.166, P < 0.05-0.001). The degrees of acute inflammation in gastric mucosal were significantly lower in mice with adjuvant than those in group A and B (H = 21 ......
您现在查看是摘要介绍页，详见PDF附件(1kb)。